Thermo Fisher Scientific Microbiology Business Sale to Astorg has officially closed, with Thermo Fisher Scientific Inc. (NYSE: TMO) confirming on August 12, 2026 that it has completed the divestiture of its microbiology business to Astorg, a leading pan-European private equity firm. The announcement, dated out of Waltham, Massachusetts, and distributed via Business Wire, sets the total consideration for the transaction at approximately $1.075 billion.
According to the disclosure, the consideration is structured as a combination of cash and a $50 million seller note. The company did not disclose the precise cash-to-note split within the $1.075 billion headline figure, nor did it specify a use-of-proceeds plan, interest terms on the note, or a maturity date, and the release contains no additional detail on those points.
The business at the center of the transaction provides antimicrobial susceptibility testing and culture media solutions. These offerings serve clinical, pharmaceutical, and food safety testing customers, according to the company’s own description of the unit. Thermo Fisher Scientific did not name specific product lines, brand names within the microbiology unit, or individual customer segments beyond these three categories in the release.
For financial context, the divested operation generated $645 million in revenue during 2025 and had been reported as part of the company’s Specialty Diagnostics segment. The release does not disclose the unit’s profitability, headcount, manufacturing footprint, or its share of the broader Specialty Diagnostics segment’s total revenue, so those figures are flagged here as undisclosed rather than estimated.
Deal Terms: How Thermo Fisher Scientific Structured the Astorg Transaction
The sale is now finalized, meaning ownership and operational control of the microbiology unit has transferred from Thermo Fisher Scientific to Astorg as of the completion date named in the release. A seller note, the instrument disclosed as part of the $50 million component, is generally understood in corporate finance as a deferred payment obligation in which the selling company effectively extends credit to the buyer as part of the purchase price, though the release does not detail the specific repayment schedule or covenants attached to this particular note.
Astorg is identified in the release solely as a leading pan-European private equity firm. The announcement does not provide additional detail on Astorg’s fund size, existing life sciences holdings, or strategic plans for the newly acquired microbiology business, and no such claims are made in this article beyond what the company has disclosed.
The completion of this transaction follows the standard mechanics of a corporate divestiture, in which a diversified company sells a business line to a third-party buyer in exchange for negotiated consideration. The release frames the transaction as complete rather than pending, distinguishing this announcement from an earlier signing or agreement-in-principle stage, though it does not specify when the deal was originally announced or signed.
What Thermo Fisher Scientific Sold in the Microbiology Business Deal
The scope of the divestiture centers on two categories of testing solutions named directly in the release: antimicrobial susceptibility testing and culture media. Antimicrobial susceptibility testing is used broadly across clinical laboratories to help determine which antimicrobial agents are effective against particular pathogens, a category that intersects with ongoing public health efforts around antimicrobial resistance. Culture media, meanwhile, support the cultivation and identification of microorganisms across clinical, pharmaceutical, and food safety testing environments, per the categories listed in the release.
Because the divested business served food safety testing customers in addition to clinical and pharmaceutical ones, the sale spans a testing footprint that touches both healthcare diagnostics and the broader food and consumer products supply chain, at least as characterized in the company’s own release. The release does not specify geographic markets served, manufacturing sites, or specific accreditation bodies associated with the divested unit.
Prior to the transaction, the business operated within Thermo Fisher Scientific’s Specialty Diagnostics segment. The release does not describe how the remaining segment will be structured going forward, nor does it provide updated segment-level revenue guidance following the divestiture, and no supplementary figures addressing this appear in the disclosure reviewed for this article.
Thermo Fisher Scientific Corporate Profile and Market Position
Thermo Fisher Scientific describes itself, in the same release announcing the microbiology business sale, as the world leader in serving science, citing annual revenue of over $45 billion. The company states its mission is to enable customers to make the world healthier, cleaner, and safer, spanning life sciences research, analytical challenges, laboratory productivity, diagnostics, and the development and manufacture of therapies.
The company’s brand portfolio, as listed in the release, includes Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon, and PPD. These brands span instruments, reagents, laboratory services, and pharmaceutical services, according to the company’s own description, though the release does not indicate whether any of these specific brand lines were included in or excluded from the divested microbiology business.
Thermo Fisher Scientific trades on the New York Stock Exchange under the ticker symbol TMO. As a publicly listed company, its disclosures of this kind are typically filed with, or referenced alongside, materials available through the U.S. Securities and Exchange Commission’s EDGAR database, where investors can review periodic reports. The release reviewed for this article does not itself constitute an SEC filing and does not reference a corresponding Form 8-K.
Transaction Overview
| Field | Detail |
|---|---|
| Transaction | Thermo Fisher Scientific microbiology business sale |
| Acquirer | Astorg (pan-European private equity firm) |
| Seller | Thermo Fisher Scientific Inc. (NYSE: TMO) |
| Total Consideration | Approximately $1.075 billion |
| Consideration Structure | Cash plus a $50 million seller note |
| Cash Component Amount | Undisclosed |
| Use of Proceeds | Undisclosed |
| Former Business Segment | Specialty Diagnostics |
| Announcement/Completion Date | August 12, 2026 |
| Deal Status | Completed |
